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assembled tau cores may be used to classify and diagnose 
disease strains. Based on these results, we propose a new 
clinicopathological classification of tauopathies based on 
the biochemical properties of tau.
Keywords Tau · Alzheimer · Pick · CBD · PSP · MAPT · 
Strains
Introduction
Tauopathies are sporadic or familial neurodegenerative dis-
eases characterized by intracytoplasmic aggregates of hyper-
phosphorylated abnormal tau protein [6, 15, 23]. Most cases 
of Alzheimer’s disease (AD), and ones of frontotemporal 
lobar degeneration associated with tauopathy (FTLD-tau), 
including cases with Pick bodies (PiD), corticobasal degen-
eration (CBD), progressive supranuclear palsy (PSP) and 
argyrophilic grain disease (AGD), are sporadic. The mor-
phology and regional distribution of pathology differ among 
these diseases, with characteristic tau pathologies being 
Abstract Intracellular filamentous tau pathology is the 
defining feature of tauopathies, which form a subset of neu-
rodegenerative diseases. We have analyzed pathological tau 
in Alzheimer’s disease, and in frontotemporal lobar degen-
eration associated with tauopathy to include cases with 
Pick bodies, corticobasal degeneration, progressive supra-
nuclear palsy, and ones due to intronic mutations in MAPT. 
We found that the C-terminal band pattern of the patho-
logical tau species is distinct for each disease. Immunoblot 
analysis of trypsin-resistant tau indicated that the different 
band patterns of the 7–18 kDa fragments in these diseases 
likely reflect different conformations of tau molecular spe-
cies. Protein sequence and mass spectrometric analyses 
revealed the carboxyl-terminal region (residues 243–406) 
of tau comprises the protease-resistant core units of the tau 
aggregates, and the sequence lengths and precise regions 
involved are different among the diseases. These unique 
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observed in degenerating neuronal and/or glial cells in each 
disease. These include neurofibrillary tangles (NFTs) in AD, 
Pick bodies in PiD, astrocytic plaques in CBD, tuft-shaped 
astrocytes in PSP, and argyrophilic grains in AGD. Various 
tau pathologies have also been reported in familial FTLD-tau 
cases caused by exonic or intronic mutations in the MAPT 
gene. They are neurofibrillary-like pathologies in cases with 
the M337V and R406W mutations, Pick body-like tau struc-
tures in cases with the G272V, S320F, K369I, and G389R 
mutations, and PSP/CBD-like glial-dominant tau pathologies 
in most cases with missense or intron mutations in exon10/
intron10 [14, 34]. Ultrastructurally, these pathological inclu-
sions consist of fibrils or filaments 10–25 nm diameter, 
composed of hyperphosphorylated tau. Reported structures 
include paired helical filaments (PHFs) (10–20 nm) in AD, 
straight filaments (15–18 nm) in PiD, straight filaments 
(13–14 nm) in PSP, twisted filaments (20 nm) in CBD, and 
twisted ribbons (15–25 nm) in cases with MAPT intronic 
mutations [4, 14]. These abnormal forms of tau are highly 
insoluble in those non-ionic and ionic detergents usually 
used for biochemical studies, such as Triton-X100 and sarko-
syl, and can be enriched by making use of this insolubility. 
Biochemical analyses of sarkosyl-insoluble tau have demon-
strated that the abnormal tau is hyperphosphorylated at more 
than 20 sites near the microtubule-binding repeat region and 
partially ubiquitinated in the repeat region [17, 27]. In AD, 
both 3-repeat (3R) and 4-repeat (4R) tau isoforms are accu-
mulated as filamentous aggregates (PHFs) [16], whereas 
only 3R tau isoforms are deposited in PiD [10], and 4R tau 
isoforms are primarily accumulated in PSP and CBD [2, 32, 
37]. It has also been reported that only 4R tau isoforms are 
deposited in MAPT intronic mutations that increase the rela-
tive expression ratios of 4R tau isoforms. Importantly, both 
CBD and PSP are 4R-tauopathies, but they can be biochemi-
cally distinguished by the banding pattern of the C-terminal 
fragments of tau [1]. Thus, the involvement of the C-terminal 
region containing the microtubule-binding domains is criti-
cal in determining the neuropathology of tauopathies. As for 
other post-translational modifications, deamidation and race-
mization of asparagine residues have been reported in AD-
tau, and the deamidation of Asn279 (located in the epitope 
of monoclonal antibody RD4) differs between AD and 4R 
tauopathies [9, 40]. Ser 262 is less phosphorylated in PiD, 
but is similarly phosphorylated in the other tauopathies [3, 
31]. Using immunoelectron microscopy of PHFs, with 
or without protease treatments, the antiparallel assembly 
model and the structural stability of the microtubule-bind-
ing domains have been suggested [5, 22, 41]. In vitro stud-
ies also showed that recombinant tau fragments containing 
the microtubule-binding domains, assembled into filaments 
by a β-sheet-like interaction [38]. Furthermore, recent stud-
ies have shown that tau fibrils made from full-length tau or 
the microtubule-binding domains can internalize and induce 
tau fibril formation in cultured cells [11, 29]. Although the 
abnormal tau species in tauopathies share many immuno-
chemical and biochemical features, little is known of the 
structural differences in abnormal tau species among the dis-
eases. It is also unknown why these tau pathologies are so 
diverse in each disease, but relatively homogeneous in indi-
vidual patients, or how they develop. A growing body of evi-
dence suggests that intracellular abnormal proteins, includ-
ing tau, have prion-like properties, i.e., they can convert 
normal proteins into an abnormal form which can be trans-
mitted from cell to cell and thereby propagated throughout 
the brain [8, 13, 28, 29]. The pattern of spread of these neu-
ronal and glial intracellular abnormal protein lesions and the 
progressive nature of the conditions can be well explained by 
such prion-like propagation of these proteins. Here we show 
that, as in prion disease, the protease-resistant tau banding 
patterns, covering the carboxy-terminal region (243–406), 
are different between the diseases, and may be useful in the 
biochemical classification of tauopathies.
Materials and methods
Brain tissues
The subjects in this study included five patients with PiD, 
nine patients with PSP, eight patients with CBD, one atypi-
cal case with pathological features of both CBD and PSP, 
eight patients with intronic MAPT mutations (7 patients 
with +16 and 1 patient with +13 mutation) and ten patients 
with AD. The age, sex, disease duration, brain weight, post-
mortem interval, and brain regions examined are given in 
Table 1 (cases no 1~27 used in the first study and additional 
cases no 28~40 are listed). Frozen brain tissues of tauopa-
thies were diagnosed by Neuropathologists at Manchester 
University, Aichi Medical University, Tokyo Metropolitan 
Institute of Gerontology, and National Center Hospital, 
National Center of Neurology and Psychiatry. The frozen 
tissues of all subjects were stored at −80 °C until analysis.
Antibodies used in this study
Antibodies used in this study were anti-tau T46 (Thermo 
Scientific), AT180 (Thermo Scientific), 12E8 [33] (a gift 
from Elan Pharmaceuticals, TauC4 [21] (a gift from Dr. 
Ihara), PHF1 (a gift from Dr. Davies), pS409 and AP422 
[27] (gifts from Dr. Ihara). The epitopes of these antibod-
ies are illustrated in Fig. 2d. The new TauC4 antibody was 
raised against synthetic peptide of IGSLDNITHVPGGGNK 
(corresponding to residues 354–369 of the 441 human tau 
isoform) with cysteine at the N-terminus conjugated with 
KLH. The new TauC4 and 12E8 antibodies were character-
ized by immunoblot analysis as shown in suppl Fig. 1a, b.
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Preparation of sarkosyl‑insoluble tau
For detection of abnormal tau accumulated in brains of 
patients, the sarkosyl-insoluble pellet was prepared as fol-
lows. Frozen brain tissue (0.2–0.5 g) was homogenized in 
20 volumes (v/w) of extraction buffer containing 10 mM 
Tris–HCl (pH 7.5), 0.8 M NaCl, 10 % sucrose, 1 mM 
EGTA, 2 % sarkosyl and incubated for 30 min at 37 °C. 
After centrifugation at 20,000×g for 10 min at 25 °C, the 
supernatants were taken, transferred to 1.5 mL tubes and 
ultracentrifuged at 100,000×g for 20 min at 25 °C. The 
pellets were washed by ultracentrifugation with 0.5 mL of 
Table 1  Description of the 
cases used in the initial study 
(no 1~27), and the additional 
cases used in the second 
study (no 28~40)
PMI postmortem interval, PiD Pick’s disease, PSP progressive supranuclear palsy, CBD corticobasal 
degeneration, MAPT (+16) cases with MAPT intron +16 mutation, AD Alzheimer’s disease, N/A not avail-
able
Diagnosis Case no. Sex Age at death (year) Duration (year) Brain (g) PMI (h)
PiD 1 F 62 10 928 N/A
PiD 2 M 56 10 1150 N/A
PSP 3 F N/A N/A N/A N/A
PSP 4 F 71 7 1070 8
PSP 18 M 74 10 1265 N/A
PSP 24 M 72 7 1290 N/A
PSP 25 F 68 9 1250 N/A
PSP 26 M 80 7 1060 N/A
CBD 5 F 74 N/A 1010 7
CBD 6 F 83 27 1024 8
CBD 7 F 80 10 990 10
CBD 17 F 65 5 950 2
CBD 23 M 71 6 1250 0.5
CBD + PSP 19 M 67 4 840 7
MAPT (+16) 8 M 55 12 1240 N/A
MAPT (+16) 9 F 65 13 1040 N/A
MAPT (+16) 10 M 46 53 1240 18
MAPT (+13) 11 M 70 5 1100 18
MAPT (+16) 27 M 65 1 N/A 24
AD 12 M 72 5 1240 2
AD 13 F 72 6 1100 4
AD 14 F 68 20 775 13
AD 15 M 80 N/A 1390 7
AD 16 F 70 N/A 1126 7
AD 20 F 65 9 1165 N/A
AD 21 F 76 13 950 N/A
AD 22 M 56 4 1350 7
PiD 28 F 58 8 1065 N/A
PiD 29 M 77 4 N/A N/A
PiD 30 M 69 10 850 N/A
PSP 31 M 88 6 1038 4.4
PSP 32 M 85 15 850 1
PSP 33 M 87 8 1120 15
CBD 34 F 87 4 1026 36
CBD 35 M 88 7 1025 15
CBD 36 F 71 8 1020 7.5
MAPT (+16) 37 F 63 15 1100 96
MAPT (+16) 38 M 66 N/A N/A N/A
AD 39 M 72 12 1251 N/A
AD 40 M 62 8 1100 24
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sterile saline, solubilized in SDS-sample buffer and sub-
jected to 4–20 % gradient polyacrylamide gel (Wako) SDS-
PAGE. Proteins were transferred to PVDF membrane, incu-
bated overnight with the anti-tau monoclonal antibody T46, 
biotinylated 2nd antibody, avidin–biotin complex (Vector) 
and developed with diaminobenzidine and nickel chlo-
ride. For preparation of trypsin-resistant tau, brain tissue 
(0.2–0.5 g) was homogenized and extracted sequentially 
with 5 volumes (v/w) of extraction buffer, buffer contain-
ing 1 % Triton-X100, and buffer containing 1 % sarkosyl. 
After incubation in 1 % sarkosyl, the sample was centri-
fuged at 20,000×g for 20 min at 25 °C. The supernatant 
was ultracentrifuged at 453,000×g for 20 min at 25 °C, 
and the sarkosyl-insoluble pellet was subjected to trypsin 
treatment.
In‑gel digestion and nano‑LC/MS/MS analysis
Sarkosyl-insoluble fractions were run on 4–20 % gradient 
gels and separated proteins corresponding to the fragments 
were excised and soaked in 50 mM Tris–HCl, pH 8.0 con-
taining 50 % acetonitrile for 30 min. The gels were dried in 
a Speed-Vac (Savant) and incubated in 50 mM Tris–HCl, 
pH 8.0 containing 125–250 ng of modified trypsin, Lys-C 
(Roche Diagnostics) or V8 (Sigma) at 37 °C for 14–20 h. 
The digests were extracted from the gel, evaporated in a 
Speed-Vac, resuspended in 0.1 % formic acid containing 
2 % acetonitrile and subjected to a DiNa HPLC system fit-
ted with an automatic sampler (KYA technology). A packed 
nano-capillary column NTCC-360/75-3-123 (0.075 mm 
I.D. × 125 mm L, particle diameter 3 µm, Nikkyo Technos) 
was used at a flow rate of 300 nl/min with a 2–80 % linear 
gradient of acetonitrile for 60 min. Eluted peptides were 
directly detected with an ion trap mass spectrometer, Velos 
Pro (Thermo Scientific). The data were analyzed with Mas-
cot (Matrix Science) software.
Expression and purification of recombinant wild‑type 
and deletion mutant of human tau
Human tau cDNA (3R1N and 4R1N) in bacterial expres-
sion plasmid pRK172 were kind gifts from Dr. Michel 
Goedert. The deletion mutants (1-163, 1-226, 3Rtau 251-
441 and 4Rtau 251-441) were constructed using PCR using 
3R1N and 4R1N in pRK172 as a template. All constructs 
were verified by DNA sequencing. Wild-type tau and the 
deletion mutants were expressed in E. coli BL21 (DE3). 
Wild-type tau, 3Rtau 251–441 and 4Rtau 251–441 were 
extracted in 50 mM Pipes buffer (pH 6.8) containing 5 mM 
EGTA, 1 mM DTT and 0.5 mM PMSF, and boiled for 
5 min. After centrifugation, the supernatants (heat-stable 
fraction) were subjected to SP-Sepharose and eluted with 
extraction buffer containing 0.5 M NaCl. The N-terminal 
tau fragments (1–163 and 1–226) were extracted in 50 mM 
Tris buffer (pH 9.0) containing 5 mM EGTA, 1 mM DTT 
and 0.5 mM PMSF, and boiled for 5 min. The supernatants 
were then subjected to Q-Sepharose and eluted with extrac-
tion buffer containing 0.5 M NaCl. The eluates were con-
centrated by 50 % saturated ammonium sulfate precipita-
tion. The pellets were resuspended in and dialyzed against 
30 mM Tris–HCl, pH 7.5.
Trypsin digestion of sarkosyl‑insoluble tau 
and purification of trypsin‑resistant tau
Sarkosyl-insoluble pellets from 0.5 to 1 g of AD, PiD, 
CBD, PSP, CBD + PSP and MAPT cortices were sus-
pended in 0.1 mL of 30 mM Tris (pH 7.5) containing 
10 mM CaCl2 by sonication. Trypsin was added at a final 
concentration of 0.5–2 mg/mL and incubated at 37 °C for 
1 h. The digestion was stopped by adding 2 % SDS for 
SDS-PAGE, or 6 M guanidine HCl for further purification, 
which was performed by size-exclusion chromatography 
on a TSK gel SW-3000 column [2.1 × 300 mm, TOSOH] 
equilibrated with 6 M guanidine HCl in 10 mM phosphate 
(pH 6.0) and on a reverse-phase HPLC with an Aquapore 
RP300 column (2.1 × 100 mm). For dephosphorylation, 
the sarkosyl-insoluble pellets or the trypsin-resistant cores 
of tau filaments were suspended in 50 mM Tris–HCl con-
taining 6 M guanidine HCl, then dialyzed overnight at 
4 °C against 50 mM Tris–HCl (pH 8.8), and centrifuged at 
20,400g for 10 min. The supernatants were incubated with 
-68
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Fig. 1  Immunoblot analysis of sarkosyl-insoluble tau in tauopathies. 
Hyperphosphorylated full-length tau (60, 64 and 68 kDa), various 
C-terminal fragments and smears were detected in the sarkosyl-insol-
uble fractions of tauopathy brains by T46 (anti-tau C-terminus). The 
banding patterns are characteristic for each disease, although the pat-
terns of fragments of CBD and MAPT (intron mutation) seem very 
similar
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E. coli alkaline phosphatase (10 U/mL; type III, Sigma) at 
67 °C for 2 h.
Protein sequence and mass spectrometric analyses 
of trypsin‑resistant tau fragments
Trypsin-resistant fragments on a PVDF membrane were 
sequenced on an Applied Biosystems 477A protein 
sequencer equipped with an online 120A PTH analyzer 
and/or a 473A protein sequencer. MALDI-TOF MS analy-
sis of purified trypsin-resistant fragments was performed 
by a Voyager-DE Pro MALDI-TOF mass spectrometer 
(PerSeptive Biosystems). To determine the C-terminal 
sequence, the purified trypsin-resistant fragments were 
digested with V8 at molar ratio of 1:20 and analyzed by 
LC/MS/MS. LC/MS/MS was performed on an ion trap 
mass spectrometer, LXQ (Thermo Fisher Scientific), with 
a reverse-phase capillary column (Develosil ODS-HG5, 
0.075 mm i.d., 50 mm or 0.075 mm i.d., 150 mm, Nomura 
Chemical) at a flow rate of 200 or 300 nl/min with a 
4–80 % linear gradient of acetonitrile.
Immunoelectron microscopy
Aliquots of the sarkosyl-insoluble fractions (1:5–10 diluted 
in DW) from tauopathy brains were placed on collodion-
coated 300-mesh nickel grids. After drying, the grids were 
blocked with 30 mM Tris–HCl, pH 7.5 containing 2 mg/
mL BSA, and incubated overnight with T46 antibody at a 
dilution of 1:500. The grids were rinsed and reacted with 
secondary antibody conjugated to 15-nm gold particles 
(1:50) to distinguish from ferritin particles, the major con-
taminants in the sarkosyl-insoluble fractions. Samples were 
stained with phosphotungstate and observed as described 
[35].
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Fig. 2  Immunoblot analysis of trypsin-resistant tau in tauopathies. a 
Immunoblot analysis of sarkosyl-insoluble tau from AD, PiD, CBD, 
PSP, CBD + PSP, and MAPT cases, before and after trypsin digestion 
with anti-tau 354–369 (TauC4). b Immunoblot analysis of trypsin-
resistant tau with 12E8. c Immunoblot analysis of trypsin-resistant 
tau with PHF1. d Schematic illustration of epitopes of antibodies 
used in this study. e Immunoblot analysis of trypsin-resistant tau pre-
pared from multiple cases of AD, PiD, CBD, PSP and MAPT cases
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Results
Sarkosyl‑insoluble C‑terminal tau fragments 
in tauopathy brains
Pathological tau in the sarkosyl-insoluble fractions from 
brains of 15 patients with neuropathologically diagnosed 
tauopathy (two cases with PiD, two cases with PSP, three 
cases with CBD, four cases with intronic mutations in 
MAPT and four cases with AD) was investigated by immu-
noblot analysis. Anti-tau antibody T46, which recognizes 
C-terminal region of tau (404–441), detected hyperphos-
phorylated full-length tau and C-terminal tau fragments 
deposited in these brains (Fig. 1). In accordance with previ-
ous reports, with two major bands being present at 60 and 
64 kDa in PiD, two major bands at 64 and 68 kDa in PSP, 
CBD and MAPT, and three bands at 60, 64 and 68 kDa 
in AD were detected, confirming that the band patterns 
of hyperphosphorylated full-length tau are useful for bio-
chemical diagnosis of 3R and 4R tauopathies. In addition 
to these full-length tau banding patterns, various C-termi-
nal fragments were characteristic for each disease. They 
included bands at 21, 34 and 39 kDa in PiD, bands at 22 
and 33 kDa in PSP, bands at 37–40 and 43 kDa in CBD and 
MAPT, and bands at 19, 22, 25, 30, 36 and 40 kDa in AD, 
such findings confirming previous reports that the 33 and 
~37 kDa bands are characteristic of PSP and CBD, respec-
tively [1].
Then, we tried to identify the N-terminal sequences 
of these other fragments by in-gel digestion with trypsin, 
Lys-C and V8 proteases followed by nano-LC/MS/MS anal-
ysis. The N-terminal sequences of these fragments identi-
fied in this study are summarized in supplementary Table 1. 
Several different N-terminal fragments were identified 
from each molecular size, suggesting that the N-termini are 
heterogeneous. Some characteristic sequences, such as 226 
VAVV and 228 VVRT, were detected in the 22–36 kD frag-
ments of AD tau, which were not detected in other tauopa-
thies, suggesting that AD-tau is distinct from those of other 
tauopathies in the C-terminal fragments. Our previous 
study, using protein sequencing together with immunoblot 
analysis, showed that the ~33 kD bands in PSP and the ~37 
kD bands in CBD contain N-terminal sequences 169–175 
and 187–192, respectively [1]. The peptide with N-terminal 
sequence 187 EPPK, which was previously identified in 
the ~37 kD fragments of CBD, was also detected in the 22 
kD band of CBD, but not in PSP. The C-terminal processed 
fragments with the same N-terminus in the fraction may be 
detected. However, this is inconsistent with previous result 
in the aspect of molecular weight. This is probably due to 
the methods used in these studies (purified fragments were 
analyzed by protein sequencing in the previous study, but 
unpurified samples were analyzed by in-gel digestion and 
LC/MS/MS in this study). Thus, it is difficult to identify the 
N-terminal sequences of these fragments from unpurified 
heterogeneous samples, even if using highly sensitive LC/
MS/MS analysis.
We presumed that these characteristic tau fragments 
may be produced by processing of full-length tau after 
aggregation and may represent different conformations 
of tau aggregates. To test this hypothesis, we investigated 
the protease-resistant tau fragments of these pathological 
tau species from tauopathy brains. To examine the struc-
tural differences of pathological tau among the diseases, 
we used trypsin treatment, because tau contains many Lys 
and Arg residues in the C-terminal region, and tryptic pep-
tides are suitable for protein sequencing and mass spec-
trometric analysis. To determine the optimum concentra-
tion of trypsin, sarkosyl-insoluble fractions of AD brains 
were treated with 0.5–2.0 mg/mL trypsin, and digestion 
of tau was monitored by immunoblotting with T46 and 
TauC4 (Suppl Fig. 2). After treatment with 0.5–2 mg/mL 
trypsin for 1 h, T46-positive full-length and smeared tau 
had completely disappeared (Suppl Fig. 2a), but trypsin-
resistant tau bands were detected at 7, 12 and 15 kDa with 
TauC4 (Suppl Fig. 2b). These results indicate that most 
of the C-terminus of tau (epitope of T46) in PHFs can 
be cleaved by trypsin, but the final microtubule-binding 
region (epitope of TauC4) is resistant to trypsin. Since 
the T46 epitope (404–441) is more C-terminal than that 
of TauC4 (354–369), it is possible that the T46 epitope is 
cleaved by trypsin whereas the TauC4 epitope is resistant 
to trypsin.
Trypsin‑resistant tau banding patterns in tauopathy 
brains
Next, we examined the trypsin-resistant tau bands from 
various tauopathy brains, including AD, PiD, CBD, PSP, 
a combination case of CBD and PSP (CBD + PSP), and 
MAPT, by means of 1.0 mg/mL trypsin treatment fol-
lowed by immunoblotting with TauC4, AT180, 12E8, 
PHF1, pS409 and AP422 (Fig. 2). TauC4 detected a 
12 kDa band in PiD, 10, 13 and 15 kDa bands in CBD, 
15, 16 kDa bands in PSP, 10, 13, 15 and 16 kDa bands 
in CBD + PSP, and 10, 13, 15, 16 and 17 kDa bands in 
MAPT (Fig. 2a). AT180, pS409 and AP422 did not detect 
any band after trypsin digestion (data not shown), but 
12E8 detected a major 12 kDa band in PiD, some weak 
bands at 10–15 kDa in CBD, PSP and CBD + PSP, and 
several strong bands at 10–17 kDa in MAPT (Fig. 2b). The 
reaction of 12E8 may be due to cross-reactivity with the 
unphosphorylated epitope. As shown in Suppl Fig. 1b, we 
confirmed that 12E8 cross-reacts with unphosphorylated 
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recombinant full-length tau and more strongly with the 
C-terminal fragment. In contrast, PHF1 detected a major 
15 kDa band in AD, weak bands at 15–17 kDa in PiD, 
PSP, CBD and CBD + PSP, and doublet bands of 17 kDa 
in MAPT (Fig. 2c). The epitopes of these antibodies are 
illustrated in Fig. 2d. Overall, the results indicate that 
microtubule-binding repeat regions, including the TauC4 
epitope, form the trypsin-resistant cores of pathological 
tau in these tauopathies, whereas the N-terminal and C-ter-
minal regions outside the repeats are trypsin sensitive. To 
examine whether the trypsin-resistant tau band patterns 
are characteristic for each disease, we prepared sarkosyl-
insoluble fractions from brains of five cases with AD, two 
cases with PiD, two cases with CBD, four cases with PSP 
and four cases with MAPT. Trypsin treatment followed by 
immunoblotting with TauC4 confirmed that each disease 
showed a consistent, characteristic band pattern of trypsin-
resistant tau (Fig. 2e). The differences in the C-terminal 
banding pattern with T46 antibody and the trypsin-resist-
ant banding pattern with TauC4 antibody were further con-
firmed by the analysis of additional 13 cases (three PiD, 
three PSP, three CBD, two MAPT and two AD cases) with 
three cases used in the first study in one western blot mem-
brane (Fig. 3a, b).
Protein sequence and mass spectrometric analyses 
of trypsin‑resistant tau in tauopathy brains
To further analyze the trypsin-resistant tau, we purified 
trypsin-resistant tau fragments from these brains. The 
trypsin-resistant tau preparations were dissolved in 6 M 
guanidine HCl and separated by gel filtration. After dialy-
sis and immunoblot analysis, these fragments were further 
purified by reverse-phase HPLC. The trypsin-resistant tau 
was analyzed by MALDI-TOF MS analysis and the results 
are summarized in Table 2. The observed mass signals were 
higher than expected molecular mass. These can be identi-
fied as the sodium adduct ions [M + Na]+. We performed 
mass analysis both before and after alkaline phosphatase 
treatment, because it has been shown that pathological tau is 
hyperphosphorylated, and that the phosphorylation inhibits 
peptide ionization. Furthermore, the N-terminal sequence of 
each band on the PVDF membrane was determined with a 
protein sequencer. The N-terminal sequences identified by 
protein sequencing and LC/MS/MS analysis together with 
MALDI-TOF MS analysis of these purified fragments are 
shown in Fig. 4. Phosphorylation was detected in some of 
these fragments, but the other post-translational modifica-
tions, such as acetylation, methylation and glycosylation 
were not detected in these fragments by this analysis.
AD tau
MALDI-TOF MS analysis of trypsin-resistant tau from 
AD brains without alkaline phosphatase treatment gave 
signals corresponding to molecular masses of 10,517.1 
(③) and 9403.2 (⑤), which match the calculated values of 
residues 268–395 and 268–385 of human 3R tau isoforms, 
and molecular masses of 10,447.2 (④) and 9330.1 (⑥) 
which match the calculated values of residues 299–395 
and 299–385 of human 4R tau isoforms (Suppl Fig. 3a). 
Mass analysis of the trypsin-resistant tau after dephospho-
rylation gave signals corresponding to molecular masses of 
11,597.7 (①), 10,517.3 (③) and 9403.2 (⑤), which match 
the calculated values of residues 268–406, 268–395 and 
268–385 of human 3R tau isoforms, and molecular masses 
of 11,526.1 (②), 10,448.3 (④), and 9330.1 (⑥), which 
match the calculated values of residues 299–406, 299–
395 and 299–385 of human 4R tau isoforms, respectively 
(Suppl Fig. 3a). Signals ① and ② were detected only when 
the fragments were dephosphorylated by alkaline phos-
phatase, suggesting that these fragments were phosphoryl-
ated. Protein sequence analysis of the three major bands at 
7, 12 and 15 kDa from AD brains revealed that all these 
bands contained two fragments of both 3R and 4R tau iso-
forms with the N-terminal sequences, HQPGGGKVQIVY 
(268–279 of 3R tau) and HVPGGGSVQIVY (299–310 
of 4R tau) (Suppl Fig. 3b). Thus, these 7, 12 and 15 kDa 
Fig. 3  Immunoblot analyses of sarkosyl-insoluble tau and the 
trypsin-resistant fragments in tauopathies (additional cases). a Immu-
noblot analysis of sarkosyl-insoluble tau from three PiD, three CBD, 
three PSP, three MAPT and four AD cases. 13 additional cases (No. 
28–40) were run on a gel with three cases (8, 15 and 23) analyzed 
in the initial study and immunoblotted with T46 antibody. b The 
trypsin-resistant tau from three PiD, three CBD, three PSP, three 
MAPT and four AD cases after the treatment of 0.1 mg/mL trypsin 
for 1 h were detected with TauC4 in a western blot membrane
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trypsin-resistant fragments consist of polypeptides with the 
same N-terminus, but different C-termini. These results are 
consistent with previous findings by Jakes et al. [20] and in 
our laboratory [18]. To further confirm the peptide identifi-
cation, we performed LC/MS/MS analysis of V8 digests of 
these fragments. Mass analysis showed signals correspond-
ing to tau peptides 392–406 (IVYKSPVVSGDTSPR), 
388–395 (HGAEIVYK) and 375–385 (THKLTFRENAK) 
(Suppl Fig. 3b), strongly suggesting that the 7, 12 and 
15 kDa AD tau bands represent tau fragments of 268–385, 
268–395 and 268–406 derived from 3R tau isoforms, and 
299–395, 299–385, and 299–406 derived from 4R tau iso-
forms (Fig. 4).
PiD tau
MALDI-TOF MS analysis of the trypsin-resistant PiD tau 
gave signals corresponding to molecular masses of 12097.0 
(①) and 11894.7 (②), which match the calculated values 
of residues 243–387 and residues 243–385 of human 3R tau 
isoforms, respectively (Table 2 and Suppl Fig. 4a). Alkaline 
phosphatase treatment had no significant effect. Protein 
sequence analysis of the major 12 kDa band revealed that 
the N-terminal sequence was LQTAPVPMPDLK, corre-
sponding to residues 243–254 of 3R tau isoforms (Suppl 
Fig. 4b). LC/MS/MS analysis of V8 digests of the frag-
ments gave signals corresponding to tau peptides 375–385 
(THKLTFRENAK) and 375–387 (THKLTFRENAKAK) 
(Suppl Fig. 4b). These results strongly suggest that the 
12 kDa PiD tau band represents tau fragments of 243–387 
and 243–385 derived from 3R tau isoforms (Fig. 4).
CBD tau
MALDI-TOF MS analysis of the CBD tryptic frag-
ments gave signals corresponding to molecular masses of 
13,757.9 (①), 12,647.3 (②), 10,750.1 (③), which match 
the calculated values of residues 268–395, 268–387 and 
268–369 of human 4R tau isoforms, respectively (Table 2 
and Suppl Fig. 5a). Alkaline phosphatase treatment had no 
significant effect (data not shown). Protein sequence anal-
ysis of 10, 13 and 15 kDa CBD tau revealed an N-termi-
nal sequence, HQPGGGK, that corresponded to residues 
268–274 of 4R tau (Suppl Fig. 5b). LC/MS/MS analysis 
Table 2  Summary of MALDI-TOF/MS/MS and immunoblot analyses of trypsin-resistant tau in tauopathy brains
Tauopathy Signal no. Measured  
MS (AP−)
Measured 
MS (AP+)
Calculated  
MS +Na(22)
Assignment 12E8(S262) PHF1 
(pS396/404)
Apparent 
MW
AD ① – 11,597.7 11,596.1 3R 268–406 – ○ 15
② – 11,527.6 11,526.1 4R 299–406 – ○ 15
③ 10,517.1 10,517.3 10,513.6 3R 268–395 – – 12
④ 10,447.2 10,448.3 10,443.5 4R 299–395 – – 12
⑤ 9403.2 9403.2 9400.0 3R 268–385 – – 7
⑥ 9330.1 9330.1 9330.0 4R 299–385 – – 7
PiD ① 12,097.0 12,095.8 12,089.5 3R 243–387 ○ – 12
② 11,894.7 11,893.8 11,890.4 3R 243–385 ○ – 12
CBD ① 13,757.9 13,756.6 13,758.3 4R 268–395 – – 15
② 12,647.3 12,645.3 12,644.8 4R 268–387 – – 13
③ 10,750.1 10,751.0 10,749.7 4R 268–369 △ – 10
PSP ① 14,599.7 ND 14,600.8 4R 260–395 ○ – 16
② 13,760.4 ND 13,758.3 4R 268–395 – – 15
③ 13,569.1 ND 13,567.3 4R 243–369 – – 15
CBD + PSP ① 14,605.3 ND 14,600.8 4R 260–395 – △ 16
② 13,760.7 ND 13,758.3 4R 268–395 – △ 15
③ 12,647.5 ND 12,644.8 4R 268–387 – – 13
④ 10,751.1 ND 10,749.7 4R 268–369 △ – 10
MAPT ① 15,685.11 + 80x4 15,684.7 15,683.3 4R 260–406 ○ ○ 17
② 14,603.9 14,603.8 14,600.8 4R 260–395 ○ – 16
③ 13,761.4 13,760.3 13,758.3 4R 268–395 – – 15
④ 12,647.7 12,647.3 12,644.8 4R 268–387 – – 13
⑤ 11,594.0 11,596.2 11,592.2 4R 260–369 ○ – 12
⑥ 10,751.5 10,751.2 10,749.7 4R 268–369 – – 10
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of V8 digests gave signals corresponding to tau peptides 
388–395 (HGAEIVYK), 375–387 (THKLTFRENAKAK) 
and 359–369 (NITHVPGGGNK) (Suppl Fig. 5b). These 
results strongly suggest that the 10, 13 and 15 kDa CBD 
bands represent tau fragments of 268–369, 268–387 and 
268–395 derived from 4R tau isoforms, respectively 
(Fig. 4).
PSP tau
MALDI-TOF MS analysis gave signals corresponding 
to molecular masses of 14,599.7 (①), 13,760.4 (②) and 
13,569.1 (③), which match the calculated values of resi-
dues 260–395, 268–395 and 243–369 of human 4R tau iso-
forms, respectively (Table 2 and Suppl Fig. 6a). Because 
recovery of trypsin-resistant PSP tau was low, we could 
not carry out protein sequence analysis. However, LC/MS/
MS analysis of V8 digests showed signals correspond-
ing to tau peptides 388–395 (HGAEIVYK) and 359–369 
(NITHVPGGGNK) (Suppl Fig. 6b). These results suggest 
that the trypsin-resistant PSP tau fragments may represent 
260–395, 268–395 and 243–369 of 4R tau isoforms. We 
also analyzed trypsin-resistant tau from one case with a 
complication of CBD and PSP. The mass analyses detected 
a mixture of the tau fragments detected in CBD and in PSP 
(Suppl Fig. 7a, b).
Tau in MAPT
MALDI-TOF mass analysis of MAPT tau with or without 
alkaline phosphatase treatment gave 6 signals correspond-
ing to molecular masses of 15,684.7 (①), 14,603.8 (②), 
13,760.3 (③), 12,647.3 (④), 11,596.2 (⑤) and 10,751.2 
(⑥), which match the calculated values of residues 268–
369, 260–369, 268–387, 268–395, 260–395 and 260–406 
of human 4R tau isoforms, respectively (Table 2 and Suppl 
Fig. 8a, b). The mass signal of 15,684.7 (①) was decreased 
after dephosphorylation suggesting that the mass signal 
of 16,005.1 (①’) may represent the mass 15,684.7(①) 
signal plus 4 phosphoric acid moieties (80 × 4 = 320); 
this matches the calculated values of residues 260–406 
of human 4R tau. As in the case of PSP tau, we could 
not detect the N-terminal sequence of trypsin-resistant 
tau. Therefore, we tried to assign the fragments based on 
AD
PiD
PSP
CBD
MAPT
Fig. 4  N-terminal sequences identified by protein sequencing, C-ter-
minal peptides identified by LC/MS/MS analysis of the V8 digests, 
or predicted sequences by MALDI-TOF MS analysis. The results of 
protein sequence analysis of each band of purified trypsin-resistant 
tau from tauopathy brains are indicated by underlining and the pep-
tides identified by LC/MS/MS analysis of V8 digestion products are 
indicated by italic characters. Possible phosphorylation sites are indi-
cated by bold letter with P
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the results of mass analyses and immunoblotting. This 
17 kDa band was immunopositive for PHF1, which is 
consistent with phosphorylation of S396/404. LC/MS/MS 
analysis of V8 digests showed signals corresponding to 
tau peptides 392–406 (IVYKSPVVSGDTSPR), 388–395 
(HGAEIVYK), 375–387 (THKLTFRENAKAK) and 359–
369 (NITHVPGGGNK) (Suppl Fig. 8b), strongly suggest-
ing that residues 260–406, 260–395, 268–395, 268–387, 
260–369 and 268–369 of 4R tau comprise the 17, 16, 15, 
13, 12 and 10 kDa trypsin-resistant fragments of MAPT, 
respectively. The trypsin-resistant core regions of patholog-
ical tau identified in this study are illustrated schematically 
in Fig. 5.
Electron microscopy of sarkosyl‑insoluble tau fibrils 
in tauopathies
Immunoelectron microscopy of the sarkosyl-insoluble frac-
tions from these tauopathy brains was performed to investi-
gate the relationship between the trypsin-resistant cores and 
the morphology of the tau fibrils. Representative pictures 
of the tau fibrils are shown in Fig. 6. In the tau fractions 
from AD brains, many fibrils with PHF morphology (10–
20 nm in diameter with 80 nm periodicity) were observed. 
Some were immunopositive for T46 antibody (Fig. 6a, b), 
but unlabeled PHFs were also observed. Similar structures 
were also observed after the trypsin digestion (Fig. 6c, d). 
In PiD, straight filaments (13–16 nm in diameter) labeled 
with T46 were observed (Fig. 6e–h). Twisted filaments (10–
25 nm in diameter with 140–180 periodicity) (Fig. 6i–l) in 
CBD and similar twisted ribbon-like filaments (10–25 nm 
diameter with broader periodicity than those of CBD) were 
seen in MAPT intronic mutations (Fig. 6q–t). On the other 
hand, thinner twisted filaments (7–15 nm in diameter with 
80–150 nm periodicity) were observed in PSP (Fig. 6m–p). 
Similar filamentous structures were observed after these 
trypsin digestion, although the numbers were significantly 
reduced (data not shown).
Discussion
Tauopathies are neurodegenerative disorders character-
ized by accumulation of abnormal tau proteins in neuronal 
and/or glial cells within the brain. In this study, we exam-
ined sarkosyl-insoluble and trypsin-resistant fragments of 
abnormal tau from brains of patients with AD, PiD, CBD, 
PSP, and intronic MAPT mutations, and found that the core 
units of the tau aggregates were composed of different tau 
repeat regions located between residues 243–406, indicat-
ing that the conformations of the aggregates are disease-
specific. These patterns of trypsin-resistant tau are remi-
niscent of the proteinase-K-resistant bands in human prion 
disorders, and suggest that tauopathies may be caused by 
Fig. 5  Summary of trypsin-
resistant regions of pathological 
tau from tauopathy brains. The 
major and minor tau fragments 
identified as trypsin-resistant 
tau in these tauopathies are 
indicated by solid and broken 
lines, respectively. Trypsin-
resistant cores of AD-tau are 
distinct from the others in 
terms of both the isoforms and 
regions. AD tau is composed of 
equimolar amounts of both 3R 
tau and 4R tau isoforms and the 
cores are localized to start from 
the middle of the 1st repeat of 
3R tau and the 2nd repeat of 4R 
tau, which are different from 
those of the other tauopathies 
composed of only 3R or only 
4R tau isoforms (20–30 amino 
acid residues slide toward the 
C-terminus)
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PSP 4R
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accumulation of toxic tau ‘prions’ in the brain. A wide 
range of phenotypic variation has been found in prion dis-
eases, and has been attributed to the existence of distinct 
“strains” of the agent or prion, and different mutations and 
polymorphisms of prion protein in the host [12, 30]. Fur-
thermore, the differences in the abnormal prion proteins in 
brains of affected patients, which are distinguished by dis-
tinct proteinase-K-resistant banding patterns, correlate with 
the disease phenotypes [39].
In this study, we show that the banding patterns of 
C-terminal fragments of tau are different among differ-
ent tauopathies, and the trypsin-resistant band patterns 
are also distinct among the diseases. Our previous study 
demonstrated that PSP and CBD differ in the pattern of 
tau fragments on immunoblots of sarkosyl-insoluble brain 
extracts [1]. The present study confirmed and extended 
these findings indicating that the differences may be 
related to the protease resistance of these pathological tau 
proteins. Employing analysis of sarkosyl-insoluble tau 
banding patterns using antibodies against tau C-terminus, 
tauopathies can be biochemically classifiable into at least 
four types, PiD, PSP, CBD and AD. In addition, we have 
shown that pathological 4R tau in MAPT intron mutation 
cases can be distinguishable from that in CBD and PSP 
cases by the analysis of the C-terminal fragments and the 
trypsin-resistant tau. These biochemical characterizations 
of pathological tau provide evidence that these diseases 
with distinct histopathologies are different disease enti-
ties with distinct tau species. It is possible that the detec-
tion of protease-resistant tau bands may also be useful 
for biochemical classification of other tauopathies with 
distinct histopathologies, such as AGD, globular glial 
Fig. 6  Electron microscopy of sarkosyl-insoluble tau from tauopathy 
brains. Electron micrographs of PHFs from AD brains, which were 
positive for T46 (a, b) which were labeled by secondary antibody 
conjugated to 15-nm gold particles. Similar PHFs were observed after 
trypsin digestion (c, d). T46-positive SFs were observed in PiD (e–h). 
Twisted filaments in CBD were positive for T46 (i–l). In PSP thin 
twisted filaments were labeled with T46 (m–p). In MAPT, ribbon-like 
filaments similar to those in CBD were observed (q–t)
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tauopathy and tangle only dementia, warranting further 
investigation.
Recent studies using cellular and animal models have 
demonstrated that intracellular pathological proteins, 
including tau protein, propagate through neuronal networks 
via prion-like mechanisms [8, 24–26]. Injection of brain 
homogenates from patients with AD, PiD, PSP, CBD and 
AGD into Tg-mice overexpressing human 4R tau induced 
tau pathologies that were similar to those of the tauopathies 
[7]. These findings strongly suggest that a structurally dis-
tinct pathological tau protein is involved in each disease, 
and has the ability to convert normal tau protein into its 
own abnormal form (seed/template-dependent prion-like 
conversion). It is likely that the protease-resistant bands 
represent the core regions of tau fibrils, and thus, it is plau-
sible that the differences in these bands in different dis-
eases reflect different conformations of the tau assemblies. 
Indeed, tau accumulated in AD brains has a unique abnor-
mal structure, i.e., paired helical filaments (PHF), and the 
microtubule-binding regions of both 3R and 4R tau form 
the core structure of PHF [19]. The sequences of trypsin-
resistant tau identified in this study in various tauopathies 
are also located in microtubule-binding regions and the 
adjacent C-terminal region, though the N- and C-terminal 
sequences and the sequence lengths differ slightly among 
the diseases. These findings suggest that the fibril cores are 
somewhat different among the diseases and the different 
structures of the assembled tau proteins may determine the 
characteristic tau pathologies. The differences in sensitivity 
to conventional staining with dyes or immunostaining may 
be due to these distinct structures [36].
As shown in Table 2, little or no differences were 
detected in the post-translational modifications of the 
trypsin-resistant tau fragments between the diseases. This 
is also similar to that seen in prion diseases, where no sig-
nificant difference of modification was identified between 
normal prion protein and the abnormal form, whereas the 
conformations between the two are different. In tauopa-
thies, the carboxy-third of tau is shown to comprise the 
protease-resistant building block of paired helical filaments 
in AD. Similar, but distinctly characteristic, C-terminal tau 
fragments were detected as the trypsin-resistant bands in 
this study. Tau mutations causing tauopathies are mostly 
concentrated in the microtubule-binding and C-terminal 
regions. In contrast, most post-translational modifications, 
such as phosphorylation, are identified surrounding the 
microtubule-binding repeat regions, namely in the trypsin-
resistant core regions of sarkosyl-insoluble tau, suggesting 
that these modifications, especially the phosphorylation, 
may occur following tau assembly and conformational 
changes.
It has been reported that Ser 262 is less phosphoryl-
ated in PiD than in other tauopathies [3, 31]. This may be 
because the epitope is buried in the cores of the tau fibrils 
in PiD (243–385, 243–387), and therefore may be hardly 
accessible for phosphorylation by kinases after assembly, 
whereas the epitope is largely located outside the fibril 
cores in other tauopathies (ex. 268–406 in AD, 267–395 
in PSP, CBD). Electron-microscopic observations revealed 
that tau is deposited as filamentous or fibrous forms with 
distinct morphologies among the diseases: PHF in AD, 
SF in PiD, twisted fibrils in CBD, and twisted ribbons in 
MAPT [4, 14]. Indeed, PHFs with 10–20 nm diameters 
in AD, SF with 13–16 nm in PiD, twisted filaments with 
10–25 nm in CBD, thin twisted filaments with 7–15 nm 
in diameter in PSP and twisted ribbon-like filaments with 
10–25 nm diameter in MAPT were observed in this study 
(Fig. 6). Thus, it seems reasonable to speculate that the 
C-terminal fragments and trypsin-resistant cores of these 
tau may be related to the fibril structures, especially the 
diameter and periodicity of the fibrils. We found 7, 10 
and 15 kDa trypsin-resistant fragments in AD, where tau 
is assembled into highly ordered PHF 10–20 nm in diam-
eter, while a ~12 kDa fragment was detected in PiD, which 
exhibits SF 13–16 nm in diameter. Several 10–25 kDa 
trypsin-resistant fragments were detected in CBD and 
MAPT, in which unique ribbon-like filamentous structures 
with 10–25 nm diameter were observed, whereas thinner 
twisted filamentous structures were observed in PSP which 
shows the unique ~33 kD CTFs and 10–16 kD trypsin-
resistant bands. Although it remains to be seen how the tau 
molecules are integrated into the fibrils, the above results 
suggest that various homodimers of tau microtubule-bind-
ing regions of 3R or 4R tau isoforms and heterodimers of 
3R/4R tau isoforms in the case of AD may be formed and 
assembled with a constant periodicity. Predicted models 
of tau fibril cores in the various tauopathies based on an 
antiparallel association are illustrated in Suppl Fig. 9.
Another important issue is the minimal unit of abnormal 
tau protein that serve as a template for prion-like propaga-
tion. Although this remains to be clarified in the case of 
prion protein, it is strongly suggested that the dimer may be 
the minimal unit in tauopathies, because an equimolar ratio 
of 3R and 4R tau isoforms is integrated into the unique 
filamentous structure (PHF) in AD, whereas fibrils com-
posed of only 3R tau or only 4R tau are deposited in other 
tauopathies. Our results suggest that it may be reasonable 
to classify the neuropathological subtypes of tauopathies 
biochemically in terms of deposition of 3R and/or 4R tau 
isoforms, the banding patterns of C-terminal fragments, 
and the protease-resistant domains. The results obtained in 
this study may also contribute to the development of PET 
probes specific for the characteristic structure of abnormal 
tau in each of the tauopathies.
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